Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer (CHEMOVA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02758652|
Recruitment Status : Recruiting
First Posted : May 2, 2016
Last Update Posted : September 18, 2019
Epithelial ovarian cancer is the most lethal gynecological malignancy in developed countries and the fifth most common cause of cancer-related death in women. Poor prognosis is due to challenges in early diagnosis and development of inevitable resistance to chemotherapy in majority of patients despite of good initial treatment response. The purpose of this prospective study is to analyze variation in microRNA expression in prediction of primary treatment response and the role of microRNAs in development of chemoresistance in epithelial ovarian cancer.
• Objectives: To screen microRNAs from prospectively collected plasma, urine and tumor samples from patients diagnosed with epithelial ovarian cancer. Samples are analyzed for microRNA expression and differential expression is correlated with primary treatment response, progression-free survival and overall survival.
• Methods: Plasma, urine and tumor samples are collected at primary surgery (open surgery or diagnostic laparoscopy) or interval debulking surgery, at 1st, 3rd and 6th neoadjuvant or adjuvant chemotherapy and at progression for high-throughput screening of microRNA expression by array technology.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer|
|Study Start Date :||May 2016|
|Estimated Primary Completion Date :||April 2026|
|Estimated Study Completion Date :||May 2026|
- miRNA expression profile as measured by miRNA array [ Time Frame: 5 years ]Expression profile calculated with bioinformatical analysis
- Progression-free survival [ Time Frame: 5 years ]Time from diagnosis to disease relapse
- Over-all survival [ Time Frame: 5 years ]Timo from diagnosis to death
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02758652
|Contact: Annika Auranen, adj firstname.lastname@example.org|
|Contact: Kalle Savolainen, MD,PhDemail@example.com|
|Principal Investigator:||Annika Auranen, adj prof||Chief of Gynecological Oncology|